Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis

Inclusion Criteria:

• Patients aged ≥ 18 years with a diagnosis of moderate to severe active RA beingprescribed filgotinib in accordance with the local standard of care and productlabel for the first time.

• Patients must be willing and able to use an electronic device to complete the studypatient-reported outcome (PRO).

Exclusion Criteria:

• Participation in any other interventional or non-interventional study without prior approval from the Medical Monitor. This does not preclude inclusion of patients enrolled to national registries.